Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shakeel Modak

Showing results (11-20 of 137) with videos related to

Pageof 14
Sort By:
Medical and Pediatric Oncology|October 12, 2002
Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumorShakeel Modak, William Gerald, Nai-Kong V Cheung
Journal of Pediatric Hematology/Oncology|July 17, 2015
Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed NeuroblastomaShakeel Modak, Alfred Asante-Korang, Laurel J Steinherz, et al.
Journal of Pediatric Hematology/Oncology|April 24, 2018
Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving ChemotherapyHannah Fassel, James B Bussel, Stephen S Roberts, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2002
Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodiesNai-Kong V Cheung, Shakeel Modak, Andrew Vickers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I studyBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Irinotecan plus temozolomide for relapsed or refractory neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Cancer|January 8, 2005
Five-day courses of irinotecan as palliative therapy for patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pediatric Blood & Cancer|November 5, 2010
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecanBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pageof 14

Showing results (11-20 of 137) with videos related to

Sort By:
Pageof 14
Medical and Pediatric Oncology|October 12, 2002
Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumorShakeel Modak, William Gerald, Nai-Kong V Cheung
Journal of Pediatric Hematology/Oncology|July 17, 2015
Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed NeuroblastomaShakeel Modak, Alfred Asante-Korang, Laurel J Steinherz, et al.
Journal of Pediatric Hematology/Oncology|April 24, 2018
Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving ChemotherapyHannah Fassel, James B Bussel, Stephen S Roberts, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2002
Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodiesNai-Kong V Cheung, Shakeel Modak, Andrew Vickers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I studyBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Irinotecan plus temozolomide for relapsed or refractory neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Cancer|January 8, 2005
Five-day courses of irinotecan as palliative therapy for patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pediatric Blood & Cancer|November 5, 2010
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecanBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pageof 14